Indication

In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated Follicular Lymphoma (Grade 1 - 3a).

Medicine details

Medicine name:
lenalidomide (Revlimid)
SMC ID:
SMC2281
Pharmaceutical company
Celgene Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
12 October 2020
Patient group submission deadline:
03 August 2020